This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 consolidated: revenue up 2%, profit after tax down 57% versus Q2 FY26
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations rose 2% year on year to Rs43,889 million; profit after tax fell 57% to Rs567 million from Rs1,328 million. The quarter included a Rs67 million exceptional charge; profit before tax was Rs548 million versus Rs1,713 million. Comparable segment figures were restated. Technology chief Mandar Ghatnekar leaves December 31, 2026; Mukesh Rathi starts January 1, 2027.
The exceptional charge and a 57% profit after tax fall may pressure sentiment; the planned technology chief handover supports continuity.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4,389 Cr | ₹4,296 Cr | +2.2% |
| Operating profit | ₹27.00 Cr | ₹90.20 Cr | −70.1% |
| Profit after tax | ₹56.70 Cr | ₹132.8 Cr | −57.3% |
| EBITDA margin | 18.8% | 19.2% | −0.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.